MetaCap

Nautilus Biotechnology (NAUT) vs 10x Genomics (TXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

10x Genomics (TXG) has outperformed Nautilus Biotechnology (NAUT) over the past year, gaining 182.4% versus a loss of 5.4%. Over five years, NAUT leads with a -56.4% price change compared with -65.2% for TXG. 10x Genomics is the larger company by market cap ($6.81 billion vs $270.0 million), about 25.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NAUT-5.36%TXG+182.44%
+458%+185%-87%
Nov 21, 20251 yearNov 20, 2026
NAUT-57.68%TXG-65.46%
+26%-37%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NAUT versus TXG key metrics
MetricNAUTTXG
Share price$2.12$51.80
Market cap$270.03M$6.81B
1-day change-2.30%-9.72%
YTD return+8.72%+217.60%
1-year return-5.36%+182.44%
5-year return-56.38%-65.20%
Forward P/E—597.67
EPS (TTM)$-0.46$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$642.82M
Revenue growth (YoY)—+5.25%
Net income (latest FY)$-59.00M$-43.54M
Gross margin—69.05%
Operating margin—-9.49%
Net margin—-6.77%
52-week high$4.31$102.81
52-week low$0.841$15.18
Distance from 52-week high-50.81%-49.62%
Analyst consensusnonebuy
Avg. price target upside+88.68%+31.54%
Average volume6.25M3.36M
Shares outstanding127.37M121.46M
Employees1281,178
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • 10x Genomics is about 25.2 times larger than Nautilus Biotechnology by market value ($6.81B vs $270.03M).
  • TXG has outperformed NAUT by 187.8 percentage points over the past year.

About Nautilus Biotechnology

NAUT stock →

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

Industrials · Biotechnology: Laboratory Analytical Instruments · 128 employees

About 10x Genomics

TXG stock →

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees

NAUT vs TXG FAQ

Which is bigger, Nautilus Biotechnology or 10x Genomics?

10x Genomics (TXG) is larger, with a market capitalization of $6.81B compared with $270.03M for Nautilus Biotechnology (NAUT).

Which stock has performed better over the past year, NAUT or TXG?

TXG returned +182.44% over the past 12 months, compared with -5.36% for NAUT (price return, excluding dividends). Past performance does not predict future results.

Are Nautilus Biotechnology and 10x Genomics in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons